Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8936130 | 0.87 | NR1H2 (0.42) | ATMMEN1KMT2ANR1H2PARP1 | |
| SCHEMBL19389920 | 0.86 | ATM (0.40) | ATMALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL6183315 | 0.86 | HSD17B10 (0.35) | ATMMEN1KMT2ANR1H2PARP1 | |
| SCHEMBL3941124 | 0.84 | ATM (0.43) | ATMALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL21360450 | 0.84 | ATM (0.43) | ATMALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL19074545 | 0.84 | MEN1 (0.34) | ATMALDH1A1MEN1KMT2ANR1H2 | |
| SCHEMBL29280769 | 0.84 | MEN1 (0.34) | ATMALDH1A1MEN1KMT2ANR1H2 | |
| SCHEMBL9696891 | 0.84 | MEN1 (0.34) | ATMALDH1A1MEN1KMT2ANR1H2 | |
| SCHEMBL25569891 | 0.83 | PARP1 (0.36) | ATMALDH1A1MEN1KMT2ANR1H2 | |
| SCHEMBL12300133 | 0.82 | HSD11B1 (0.34) | ATMALDH1A1MEN1KMT2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-08-31 | — | — | US | disclosed |
| US-11654197-B2 | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654197-B2 | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same | GABRP, GABRD, GABBR2 | ATM 3234/4885ALDH1A1 1783/4885MEN1 3471/4885 |
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | BCR, PIN1, PAICS | ATM 3659/4885ALDH1A1 2134/4885MEN1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.